novopro retatrutide vs Mounjaro: triple agonist versus dual agonist compared Retatrutide 30mg – NewBioRx

Tirzepatide relies heavily on the synergy between GLP-1 and GIP

More people achieved at least a 5% weight reduction, but the drug caused higher rates of mild-to-moderate gastrointestinal issues

GLP-1 therapy benefits men experiencing metabolic changes and stubborn weight gain

The drug must be treating that condition, not simply supporting general wellness

see the EMC SmPC and NHS Wegovy page [13] Tirzepatide (Mounjaro) approved by the MHRA with NICE guidance in place (NICE TA924)

Starting low and titrating slowly while monitoring both weight and alcohol-related outcomes allows identification of the minimum effective dose for each individual